expect back-end acceler met
fundament stori remain intact visibl durabl mid-
singl digit growth reason hill-rom
object new ceo john groetelaar journey
result line overal ex-u weaker hill-rom report
revenu line mse repres core growth
vs mse ep estim primarili
result lower tax posit quarter includ us strength pt
momentum acceler margin line estim
pipelin commentari compani track exceed
pipelin revenu year ytd centrella mix increas
medsurg vs last quarter howev ex-u momentum deceler pt
inclus oem issu surgic solut pt anniversari larg
middl east order pt even net item core intern growth
repres pt momentum deceler disappoint
acceler thesi intact downgrad hill-rom equal-weight
start year prior transform thesi becam reflect consensu
estim appoint new ceo john groetelaar eas comp
build pipelin expect elev top-line momentum
acceler result core growth line guidanc
core growth pt easier comp pipelin build
littl disappoint investor surgic oem issu like cost bp
core growth admittedli investor grow wari creativ way
determin core growth versu organ number said
convinc fundament realli chang comfort
upper end rang manag tri establish track
record meet expect choppier perform last year initi
success year
oper leverag remain bright spot hill-rom continu expect bp
gross margin bp oper margin expans year margin
bright spot last quarter continu model peer
expans bp howev see top-line
import multipl expans ep growth go forward given margin
improv date convinc new ceo john groetelaar
reinvest materi rather think growth focu
pipelin progress encourag pipelin product revenu ytd
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
indic hill-rom track exceed target outlook
continu posit centrella account medsurg
versu last quarter account revenu includ competit
convers acceler bed replac cycl recent
expans ophthalmolog franchis front retinavu
partnership uptak spotvis indic expans drive
flc growth see debat flc drive growth multipl
expans integr tabl motion grew quarter sustain
high attach rate da vinci xi placement linq could open
market see full launch later calendar year
contribut
earli thought year expect increment focu
growth materi deviat updat lrp announc last
year see crawl lrp call core growth
compound-annual-growth-rate report oper margin
think organ growth next year bp margin expans
good guidepost consist model
remain equal-weight pt discuss downgrad earlier
year continu see lrp achiev believ hill-rom
transform increasingli reflect consensu estim solid execut
drive multipl expans hill-rom
multipl re-rat given divers improv growth
multipl re-rat given divers improv growth
price target reflect ev/ebitda multipl
discount smid cap med-tech given leverag lower growth
new product launch growth exceed expect cost initi
take margin higher new product launch perform better expect
underli margin surpass top hill-rom long-rang plan given upsid
welch allyn organ initi hill-rom manag remain focus
addit deal compani delev
hill-rom growth stabil mid-singl digit north america growth slow
given limit bed contribut tailwind welch allyn surgic
new product move hill-rom structur organ growth rate
welch allyn synergi mix cost initi drive margin
improv stabil growth visibl margin improv drive
long-term plan materi sale see moder growth
surgic solut see neg growth north america
moder organ initi materi manag expect leav
welch allyn driven improv mix synergi multipl fall given
compani high debt load
hill-rom multipl re-rat
growth move higher volatil
decreas hill-rom sale base
diversifi number driver
increas hill-rom organ
lrp achiev
achiev prior lrp target year earli
hill-rom new lrp call growth
trend toward
along oper margin
target see new lrp
achiev product pipelin
robust time around end market
mix improv
hospit capital-expenditure environ hill-
rom revenu expos hospit
centrella contribut
sale expect contribut
sale
progress cost restructur on-going
uptak recent product launch
shift capital-expenditure spend environ
risk achiev price
futur sale lower expect
european sale continu declin
organ leverag prove difficult
materi shift capital-expenditure environ given
million except ep
product sale servic
good sold
dollar million except per share data
total revenu
less net incom non-controlling interest
net incom sharehold
dollar million except per share data
dollar million except per share data
invest invest secur
softwar net
note receiv net discount
accru pension postretir benefit
addit paid capit
dollar million except per share data
net realiz capit loss gain equiti method invest incom loss
provis defer incom tax
chang oper asset liabil
net provid oper activ
capit expenditur purchas intang
proce dispos properti equip leas
proce sale non-strateg asset
payment acquisit busi net cash
invest purchas capit call
proce invest sale matur
net use invest activ
net chang short-term debt net debt issuanc cost
payment long-term debt net proce settlement interest rate swap includ payment/borrow revolv
distribut non-controlling interest partner
net chang equiti
effect exchang rate ce
net chang
equival bop
equival eop
